vs

Side-by-side financial comparison of A.K.A. BRANDS HOLDING CORP. (AKA) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

Orthofix Medical Inc. is the larger business by last-quarter revenue ($219.9M vs $163.9M, roughly 1.3× A.K.A. BRANDS HOLDING CORP.). Orthofix Medical Inc. runs the higher net margin — -1.0% vs -8.8%, a 7.8% gap on every dollar of revenue. On growth, A.K.A. BRANDS HOLDING CORP. posted the faster year-over-year revenue change (3.1% vs 2.0%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $-3.0M). Over the past eight quarters, A.K.A. BRANDS HOLDING CORP.'s revenue compounded faster (18.5% CAGR vs 8.0%).

Yum! Brands, Inc. is an American multinational fast food corporation. It was formed in 1977 as a subsidiary of PepsiCo, after the company acquired KFC, Pizza Hut, and Taco Bell. PepsiCo divested the brands in 1997, and these consolidated as Yum!. The company operates KFC, Pizza Hut, Taco Bell, Habit Burger & Grill, and several technology companies.

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

AKA vs OFIX — Head-to-Head

Bigger by revenue
OFIX
OFIX
1.3× larger
OFIX
$219.9M
$163.9M
AKA
Growing faster (revenue YoY)
AKA
AKA
+1.1% gap
AKA
3.1%
2.0%
OFIX
Higher net margin
OFIX
OFIX
7.8% more per $
OFIX
-1.0%
-8.8%
AKA
More free cash flow
OFIX
OFIX
$19.9M more FCF
OFIX
$16.8M
$-3.0M
AKA
Faster 2-yr revenue CAGR
AKA
AKA
Annualised
AKA
18.5%
8.0%
OFIX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AKA
AKA
OFIX
OFIX
Revenue
$163.9M
$219.9M
Net Profit
$-14.5M
$-2.2M
Gross Margin
55.6%
71.1%
Operating Margin
-6.6%
0.2%
Net Margin
-8.8%
-1.0%
Revenue YoY
3.1%
2.0%
Net Profit YoY
-55.0%
92.4%
EPS (diluted)
$-1.35
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AKA
AKA
OFIX
OFIX
Q4 25
$163.9M
$219.9M
Q3 25
$147.1M
$205.6M
Q2 25
$160.5M
$203.1M
Q1 25
$128.7M
$193.6M
Q4 24
$159.0M
$215.7M
Q3 24
$149.9M
$196.6M
Q2 24
$148.9M
$198.6M
Q1 24
$116.8M
$188.6M
Net Profit
AKA
AKA
OFIX
OFIX
Q4 25
$-14.5M
$-2.2M
Q3 25
$-5.0M
$-22.8M
Q2 25
$-3.6M
$-14.1M
Q1 25
$-8.3M
$-53.1M
Q4 24
$-9.4M
$-29.1M
Q3 24
$-5.4M
$-27.4M
Q2 24
$-2.3M
$-33.4M
Q1 24
$-8.9M
$-36.0M
Gross Margin
AKA
AKA
OFIX
OFIX
Q4 25
55.6%
71.1%
Q3 25
59.1%
72.2%
Q2 25
57.5%
68.7%
Q1 25
57.2%
62.8%
Q4 24
55.9%
69.0%
Q3 24
58.0%
68.7%
Q2 24
57.7%
67.8%
Q1 24
56.2%
67.5%
Operating Margin
AKA
AKA
OFIX
OFIX
Q4 25
-6.6%
0.2%
Q3 25
-1.0%
-8.3%
Q2 25
-0.3%
-7.9%
Q1 25
-4.2%
-25.2%
Q4 24
-1.8%
-5.3%
Q3 24
-1.4%
-9.6%
Q2 24
0.4%
-12.5%
Q1 24
-5.2%
-15.6%
Net Margin
AKA
AKA
OFIX
OFIX
Q4 25
-8.8%
-1.0%
Q3 25
-3.4%
-11.1%
Q2 25
-2.3%
-6.9%
Q1 25
-6.5%
-27.4%
Q4 24
-5.9%
-13.5%
Q3 24
-3.6%
-13.9%
Q2 24
-1.5%
-16.8%
Q1 24
-7.6%
-19.1%
EPS (diluted)
AKA
AKA
OFIX
OFIX
Q4 25
$-1.35
$-0.05
Q3 25
$-0.46
$-0.57
Q2 25
$-0.34
$-0.36
Q1 25
$-0.78
$-1.35
Q4 24
$-0.88
$-0.76
Q3 24
$-0.51
$-0.71
Q2 24
$-0.22
$-0.88
Q1 24
$-0.85
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AKA
AKA
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$20.3M
$82.0M
Total DebtLower is stronger
$111.1M
Stockholders' EquityBook value
$97.8M
$450.0M
Total Assets
$397.4M
$850.6M
Debt / EquityLower = less leverage
1.14×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AKA
AKA
OFIX
OFIX
Q4 25
$20.3M
$82.0M
Q3 25
$23.4M
$62.9M
Q2 25
$23.1M
$65.6M
Q1 25
$26.7M
$58.0M
Q4 24
$24.2M
$83.2M
Q3 24
$23.1M
$30.1M
Q2 24
$25.5M
$26.4M
Q1 24
$21.9M
$27.0M
Total Debt
AKA
AKA
OFIX
OFIX
Q4 25
$111.1M
Q3 25
$111.3M
$157.2M
Q2 25
$108.7M
$157.0M
Q1 25
$119.9M
$156.9M
Q4 24
$111.7M
$157.0M
Q3 24
$118.5M
Q2 24
$106.9M
$118.0M
Q1 24
$103.6M
$118.2M
Stockholders' Equity
AKA
AKA
OFIX
OFIX
Q4 25
$97.8M
$450.0M
Q3 25
$110.1M
$442.5M
Q2 25
$114.1M
$458.3M
Q1 25
$111.5M
$458.3M
Q4 24
$117.6M
$503.1M
Q3 24
$136.9M
$525.9M
Q2 24
$136.6M
$546.0M
Q1 24
$135.5M
$570.3M
Total Assets
AKA
AKA
OFIX
OFIX
Q4 25
$397.4M
$850.6M
Q3 25
$411.3M
$832.6M
Q2 25
$410.8M
$837.2M
Q1 25
$396.6M
$823.1M
Q4 24
$385.2M
$893.3M
Q3 24
$404.1M
$867.9M
Q2 24
$388.8M
$882.0M
Q1 24
$355.8M
$906.0M
Debt / Equity
AKA
AKA
OFIX
OFIX
Q4 25
1.14×
Q3 25
1.01×
0.36×
Q2 25
0.95×
0.34×
Q1 25
1.08×
0.34×
Q4 24
0.95×
0.31×
Q3 24
0.23×
Q2 24
0.78×
0.22×
Q1 24
0.76×
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AKA
AKA
OFIX
OFIX
Operating Cash FlowLast quarter
$1.7M
$27.7M
Free Cash FlowOCF − Capex
$-3.0M
$16.8M
FCF MarginFCF / Revenue
-1.9%
7.6%
Capex IntensityCapex / Revenue
2.9%
4.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-633.0K
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AKA
AKA
OFIX
OFIX
Q4 25
$1.7M
$27.7M
Q3 25
$4.7M
$12.4M
Q2 25
$11.9M
$11.6M
Q1 25
$-1.9M
$-18.4M
Q4 24
$7.0M
$23.7M
Q3 24
$-2.1M
$11.7M
Q2 24
$3.5M
$9.0M
Q1 24
$-7.7M
$-18.6M
Free Cash Flow
AKA
AKA
OFIX
OFIX
Q4 25
$-3.0M
$16.8M
Q3 25
$317.0K
$2.5M
Q2 25
$7.4M
$4.5M
Q1 25
$-5.3M
$-25.1M
Q4 24
$3.1M
$15.2M
Q3 24
$-7.1M
$6.3M
Q2 24
$1.5M
$-360.0K
Q1 24
$-8.4M
$-29.1M
FCF Margin
AKA
AKA
OFIX
OFIX
Q4 25
-1.9%
7.6%
Q3 25
0.2%
1.2%
Q2 25
4.6%
2.2%
Q1 25
-4.1%
-13.0%
Q4 24
2.0%
7.0%
Q3 24
-4.7%
3.2%
Q2 24
1.0%
-0.2%
Q1 24
-7.2%
-15.4%
Capex Intensity
AKA
AKA
OFIX
OFIX
Q4 25
2.9%
4.9%
Q3 25
3.0%
4.8%
Q2 25
2.8%
3.5%
Q1 25
2.7%
3.5%
Q4 24
2.5%
4.0%
Q3 24
3.3%
2.7%
Q2 24
1.3%
4.7%
Q1 24
0.6%
5.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AKA
AKA

Segment breakdown not available.

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons